COSCIENS Biopharma Inc
cosciensbio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2025 20-F, filed Mar 25, 2026. Its latest SEC filing is a 15-12G from Jul 6, 2026.
20-F for FY2025, filed Mar 25, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Develops and sells natural, plant-based active ingredients derived from oats and other renewable resources for personal care, cosmetics, and human and animal health markets. Also commercializes Macrilen, an oral test for diagnosing adult growth hormone deficiency.
20-F for FY2025, filed Mar 25, 2026
Who Were Their Customers?
It sells active ingredients directly and through distributors to businesses in personal care, cosmetics, medical and animal health; it markets veterinary products to veterinarians in Japan and other Asian countries.
20-F for FY2025, filed Mar 25, 2026COSCIENS is a life science company focused on the development and commercialization of natural, plant-based active ingredients derived from…View ↗
20-F for FY2025, filed Mar 25, 2026
During the year ended December 31, 2025, the Company had sales to one major customer representing 84% of total revenue (2024 - 79% of total…View ↗
Did Revenues Turn Into Profits?
No. It lost $10.4M in .
20-F for FY2025, filed Mar 25, 2026
How Were They Changing?
Business focus
The older report centers the business on developing and commercializing Macrilen and a therapeutic pipeline; the latest centers its business description on oat-based active ingredients and extraction technology.
20-F for FY2022, filed Mar 23, 2023 20-F for FY2025, filed Mar 25, 2026
Loading...
